However, the anti‐tumor efficacy of these DDR1 inhibitors which depend on DDR1 signaling for cancer cells survival is limited to suppress tumor growth and not sufficient to induce complete tumor regression in vivo. The gene discussed is DDR1; the disease is neoplasm.